
Jacque Duncan
Department Chair · University of California (San Francisco) School of Medicine
Credentials: · · ·
History
- 2024–Present
School of Medicine/UCSF Health Partnership
2022–PresentDepartment of Ophthalmology · UCSF Medical Center
- 2000–2001
- 1999–2000
- 1998–1999
Medical Retina and Inherited Retinal Degenerations
1995–1998
Research
Interim results from the international trial of Second Sight's visual prosthesis
Ophthalmology · 2012 · 473 citations
Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial
Ophthalmology · 2016 · 250 citations
High-resolution imaging with adaptive optics in patients with inherited retinal degeneration
Investigative Ophthalmology & Visual Science · 2007 · First of 8 authors · Corresponding · 222 citations
- MP
22 papers

19 papers

13 papers

13 papers

11 papers
- AM
11 papers

11 papers
- RH
10 papers
Grants
- 2022–2027
NAC Attack AOSLO Reading Center
National Eye Institute · UG1
Contact PI · $915.3K · University of California, San Francisco
- 2025–2026
Development of a Novel, Noninvasive, Sensitive Measure of Retinal Dysfunction
National Eye Institute · R21
PI · $450.5K · University of California, San Francisco
- 2014–2026
Advanced Technology to Study Visual Function on a Cellular Scale
National Eye Institute · R01
PI · $9.9M · University of California Berkeley
- 2022–2026
Expert Curation of Clinically Significant Variants in Genes for Early Onset Retinal Degeneration
National Eye Institute · U24
Contact PI · $1.1M · University of California, San Francisco
Clinical trials
- 2012–2019
Principal investigator · Completed · Phase 2
Neurotech Pharmaceuticals
- 2005–2028
Retinal Imaging in Patients With Inherited Retinal Degenerations
Principal investigator · Recruiting
University of California, San Francisco
- 2017–2029
Rate of Progression in USH2A-related Retinal Degeneration
Study chair · Active not recruiting
Jaeb Center for Health Research
- 2023–2033
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
Site PI · Recruiting · Phase 3
Atsena Therapeutics Inc.

